Correction Open Access
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Nov 9, 2022; 11(6): 387-389
Published online Nov 9, 2022. doi: 10.5492/wjccm.v11.i6.387
Correction to “Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital”
Jose I Iglesias, Department of Critical Care, Community Medical Center, Toms River, NJ 08757, United States
Andrew V Vassallo, Department of Pharmacy, Community Medical Center, Toms River, NJ 08757, United States
ORCID number: Jose I Iglesias (0000-0001-7851-0498).
Author contributions: Iglesias JI did the formal analysis; Vassallo AV did the original draft editing and project administration; all authors participate in the manuscript conceptualization, methodology and original draft writing.
Conflict-of-interest statement: All authors report no relevant conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jose I Iglesias, DO, FASN, Department of Critical Care, Community Medical Center, 99 W Rt 37, Toms River, NJ 08757, United States. jiglesias23@gmail.com
Received: May 4, 2022
Peer-review started: May 4, 2022
First decision: June 16, 2022
Revised: June 23, 2022
Accepted: September 22, 2022
Article in press: September 22, 2022
Published online: November 9, 2022
Processing time: 183 Days and 8.1 Hours

Abstract

Correction to: “Iglesias JI et al. Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. World J Crit Care Med 2021 Sep 9; 10(5): 244-259. DOI: 10.5492/wjccm.v10.i5.244. PMID: 34616660; PMCID: PMC8462025.” In this article, corrections were made to Tables.

Key Words: Corrections; COVID-19; Corticosteroids; Intensive care unit; Methylprednisolone; Tociluzimab; Anti-inflammatory

Core Tip: This manuscript is an author’s correction for “Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital.” World J Crit Care Med 2021 Sep 9; 10(5): 244-259. DOI: 10.5492/wjccm.v10.i5.244. PMID: 34616660; PMCID: PMC8462025.
TO THE EDITOR

Correction to: Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y, Patel VV, Patel N, Ayad L, Benson P, Pittiglio M, Gobran E, Clark A, Khan W, Damalas K, Mohan R, Singh SP. Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. World J Crit Care Med 2021 Sep 9; 10(5): 244-259. DOI: 10.5492/wjccm.v10.i5.244. PMID: 34616660; PMCID: PMC8462025[1].

In the original manuscript, there are some errors in the table data presented, which need to be modified. The corrected tables are shown as Table 1 (original Table 1) and Table 2 (original Table 4). These errors do not change the ultimate results and conclusion of the paper but have been provided for clarification and overall accuracy.

Table 1 Coronavirus disease 2019 patients admitted to intensive care unit characteristics of survivors and non-survivors.
Non-survivor (n = 167)
Survivors (n = 94)
P value
OR
95%CI
Age 72 (63-82)65.5 (51-74)< 0.001
Race (Caucasian)125 (74.9)57 (60.6)0.0161.91.12-3.3
BMI29 (23.9, 34.7)28.6 (24, 33)0.49
Sex (male)102 (61)56 (60)0.811.0650.63-1.78
Diabetes60 (35)24 (26)0.081.630.93-2.8
CHF24 (15)10 (11)0.381.420.64-3.1
CAD45 (27)20 (21)0.301.360.74-2.48
COPD38 (23)23 (25)0.750.90.5-1.64
CKD25 (15)13 (14)0.81.090.53-2.26
HTN100 (60)45 (48)0.0611.620.97-2.70
AKI87 (52)30 (32)0.0022.31.21-2.5
Mechanical ventilation134 (80)44 (47)< 0.0014.62.64-8
Hemodialysis29(18)10 (11)0.131.80.83-3.8
Neutrophils × 109/L7.4 (5-11.79)7.8 4.4-12.90.92
Lymphocytes0.7 (0.5, 1.2)0.9 (0.6, 1.6)0.011
Neutrophil/lymphocyte10 (6, 18.5)7.54 4.3-14.20.017
SCr (mg/dL)1.2 (0.8-1.8)1.1 (0.8, 0.8)0.49
Plts (× 109/L)202 (166-268)232 (155-301)0.27
Tbili (mg/dl)0.5 (0.4, 0.8)0.5 (0.4, 0.8)0.65
SOFA admit4 (3-7)4 (2, 6)0.095
PaO2/FIO2190 (76, 285)232 (123, 307)0.039
PaO269 (55-86)73 (59-96)0.083
FIO20.44 (0.24-1)0.36 (0.21-0.97)0.12
OR: Odds ratio; CI: Confidence interval; CAD: Coronary artery disease; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; CHF: Congestive heart failure; AKI: Acute kidney injury; HD: Hemodialysis; tBili: Total bilirubin; Plts: Platelets INR: International normalized ratio; PaO2/FiO2: Partial pressure of oxygen/inspired concentration of oxygen ratio; SOFA: Sequential Organ Failure Assessment; BMI: Body mass index; SCr: Serum creatinine.
Table 2 Inflammatory markers in coronavirus disease 2019 survivors and non-survivors.
Non-survivors (n = 167)
Survivors (n = 94)
P value
IL-6 day 1 (pg/mL)116 (33, 410)72 (45, 210)0.75
IL-6 day 2 470 (36, 1299)153 (10, 280)0.38
D-Dimer day 1 (ng/mL)855 (522, 2434)595 (337, 1349)0.013
D-Dimer day 2691 (436, 1743)1040 (550, 3431)0.11
CRP day 1 (mg/L)125 (61, 179)130 (89, 185)0.55
CRP day 2116 (82, 185)119 (47, 175)0.29
Ferritin day 1 (ng/mL)869 (406, 1467)995 (488, 1571)0.35
Ferritin day 2822 (447, 1432)1053 (712, 2057)0.05
IL-6: Interleukin 6, CRP: C-reactive protein.

Patient characteristics are described in Table 1. Univariate predictors of decreased survival included the need for mechanical ventilation, acute kidney injury, Caucasian race, older age, lower total lymphocyte count, higher neutrophil/Lymphocyte ratio, and a greater degree of respiratory failure manifested by a lower PaO2/FIO2 ratio. As anticipated non-survivors demonstrated a higher degree of elevated inflammatory and pro-thrombotic markers, D-Dimer at 24 h (Table 2, Original Table 4).

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Critical care medicine

Country/Territory of origin: United States

Peer-review report’s scientific quality classification

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Ata F, Qatar; Aydin S, Turkey; Yu L, Singapore; Yu L, Singapore S-Editor: Wu YXJ L-Editor: A P-Editor: Wu YXJ

References
1.  Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y, Patel VV, Patel N, Ayad L, Benson P, Pittiglio M, Gobran E, Clark A, Khan W, Damalas K, Mohan R, Singh SP. Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. World J Crit Care Med. 2021;10:244-259.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]